Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience

AimTo evaluate the effects of insulin degludec/insulin aspart (IDegAsp) coformulation as an intensification of insulin treatment for glycemic control in patients with type 2 diabetes (T2D) in a long term real-world clinical setting.Materials and MethodsThis retrospective non-interventional study, in...

Full description

Bibliographic Details
Main Authors:	Hatice Oner, Hatice Gizem Gunhan, Dilek Gogas Yavuz
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Clinical Diabetes and Healthcare
Subjects:	Keywords: IDegAsp1 insulin2 degludec3 real world4 type 2 diabetes5 intensification6
Online Access:	https://www.frontiersin.org/articles/10.3389/fcdhc.2022.783277/full

Similar Items

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
by: Sarah J. Glastras, et al.
Published: (2020-04-01)

Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment)
by: Jothydev Kesavadev, et al.
Published: (2021-12-01)

Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India
by: Rajiv Kovil
Published: (2022-01-01)

Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013-01-01)

Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
by: Tarık Kırkgöz, et al.
Published: (2022-03-01)

Insulin degludec aspart: One-year real world experience
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
by: Siew Pheng Chan, et al.
Published: (2023-05-01)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
by: Kyu Yong Cho, et al.
Published: (2020-08-01)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
by: Qiong Luo, et al.
Published: (2022-10-01)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
by: Shinje Moon, et al.
Published: (2021-09-01)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
by: Minze MG, et al.
Published: (2016-03-01)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
by: Hongzhong Liu, et al.
Published: (2022-04-01)

Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting
by: Alex Ramírez-Rincón, et al.
Published: (2022-04-01)

Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes
by: Han Na Jang, et al.
Published: (2022-01-01)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
by: Han Na Jang, et al.
Published: (2019-12-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Degludec insulin: A novel basal insulin
by: Sanjay Kalra, et al.
Published: (2011-01-01)

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
by: Rendell M
Published: (2017-04-01)

Efectividad de IDegLira para el manejo de la diabetes tipo 2 durante la pandemia Covid -19: un seguimiento a través de teleconsulta
by: Gustavo Adolfo Parra Serrano, et al.
Published: (2022-10-01)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01)

Patient reported attitude, practice, satisfaction, and quality of life on insulin degludec/insulin aspart: A single-center survey from India in adult with diabetes
by: Rajiv Kovil
Published: (2022-01-01)

Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system
by: Psota M, et al.
Published: (2017-12-01)

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01)

Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes
by: Debmalya Sanyal, et al.
Published: (2021-03-01)

The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia
by: G. R. Galstyan
Published: (2023-02-01)

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
by: Lyudmila Alexandrovna Suplotova, et al.
Published: (2015-12-01)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)

A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus
by: A. S. Pogorelova
Published: (2018-07-01)

Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
by: Ran Wei, et al.
Published: (2023-08-01)

Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yunjiao Yang, et al.
Published: (2022-05-01)

Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
by: Guangxin Han, et al.
Published: (2022-11-01)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
by: Mitsuhisa Komatsu, et al.
Published: (2021-09-01)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
by: Mizuho Yamabe, et al.
Published: (2019-03-01)

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
by: Eman N. Alhmoud, et al.
Published: (2024-01-01)

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study
by: Stefano Tumini, et al.
Published: (2020-04-01)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
by: Richard E. Pratley, et al.
Published: (2019-11-01)

Future of newer basal insulin
by: S V Madhu, et al.
Published: (2013-01-01)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
by: Junko Oya, et al.
Published: (2021-11-01)

Use of insulin degludec in pregnancy: two case reports and a literature review
by: E. Sprio, et al.
Published: (2020-11-01)